Follow
Carlo Visco
Carlo Visco
MD
Verified email at univr.it
Title
Cited by
Cited by
Year
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression …
S Hu, ZY Xu-Monette, A Tzankov, T Green, L Wu, A Balasubramanyam, ...
Blood, The Journal of the American Society of Hematology 121 (20), 4021-4031, 2013
8172013
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin …
TM Green, KH Young, C Visco, ZY Xu-Monette, A Orazi, RS Go, O Nielsen, ...
Journal of clinical oncology 30 (28), 3460-3467, 2012
8152012
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ...
The Lancet Haematology 7 (10), e737-e745, 2020
5582020
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
D Rossi, V Spina, C Deambrogi, S Rasi, L Laurenti, K Stamatopoulos, ...
Blood, The Journal of the American Society of Hematology 117 (12), 3391-3401, 2011
4332011
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large …
C Visco, Y Li, ZY Xu-Monette, RN Miranda, TM Green, A Tzankov, W Wen, ...
Leukemia 26 (9), 2103-2113, 2012
4092012
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP …
ZY Xu-Monette, L Wu, C Visco, YC Tai, A Tzankov, W Liu, ...
Blood, The Journal of the American Society of Hematology 120 (19), 3986-3996, 2012
3992012
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL …
S Hu, ZY Xu-Monette, A Balasubramanyam, GC Manyam, C Visco, ...
Blood, The Journal of the American Society of Hematology 121 (14), 2715-2724, 2013
2832013
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
D Rossi, L Terzi-di-Bergamo, L De Paoli, M Cerri, G Ghilardi, A Chiarenza, ...
Blood, The Journal of the American Society of Hematology 126 (16), 1921-1924, 2015
2632015
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation
C Visco, S Finotto, R Zambello, R Paolini, A Menin, R Zanotti, F Zaja, ...
Journal of clinical oncology 31 (11), 1442-1449, 2013
2392013
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International …
C Visco, A Tzankov, ZY Xu-Monette, RN Miranda, YC Tai, Y Li, W Liu, ...
Haematologica 98 (2), 255, 2013
1972013
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection
L Arcaini, C Besson, M Frigeni, H Fontaine, M Goldaniga, M Casato, ...
Blood, The Journal of the American Society of Hematology 128 (21), 2527-2532, 2016
1842016
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi
L Arcaini, D Vallisa, S Rattotti, VV Ferretti, AJM Ferreri, P Bernuzzi, ...
Annals of Oncology 25 (7), 1404-1410, 2014
1742014
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
A Tzankov, ZY Xu-Monette, M Gerhard, C Visco, S Dirnhofer, N Gisin, ...
Modern pathology 27 (7), 958-971, 2014
1712014
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo …
F Merli, S Luminari, F Ilariucci, M Petrini, C Visco, A Ambrosetti, ...
British journal of haematology 156 (3), 346-353, 2012
1622012
Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries
CY Ok, L Li, ZY Xu-Monette, C Visco, A Tzankov, GC Manyam, ...
Clinical Cancer Research 20 (9), 2338-2349, 2014
1592014
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi
C Visco, A Chiappella, L Nassi, C Patti, S Ferrero, D Barbero, ...
The Lancet Haematology 4 (1), e15-e23, 2017
1462017
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia
C Visco, M Ruggeri, M Laura Evangelista, R Stasi, R Zanotti, I Giaretta, ...
Blood, The Journal of the American Society of Hematology 111 (3), 1110-1116, 2008
1422008
Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL
ZY Xu-Monette, M Xiao, Q Au, R Padmanabhan, B Xu, N Hoe, ...
Cancer immunology research 7 (4), 644-657, 2019
1322019
Autoimmune cytopenias in chronic lymphocytic leukemia
C Visco, W Barcellini, F Maura, A Neri, A Cortelezzi, F Rodeghiero
American journal of hematology 89 (11), 1055-1062, 2014
1302014
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
Q Ye, ZY Xu-Monette, A Tzankov, L Deng, X Wang, GC Manyam, C Visco, ...
Oncotarget 7 (3), 2401, 2016
1282016
The system can't perform the operation now. Try again later.
Articles 1–20